Chronic Inflammation and Susceptibility to Bacterial Infections in Mice Lacking the Polypeptide (p)105 Precursor  (NF-κB1) but Expressing p50 by Ishikawa, Hideaki et al.
 
985
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/98/04/985/12 $2.00
Volume 187, Number 7, April 6, 1998 985–996
http://www.jem.org
 
Chronic Inﬂammation and Susceptibility to Bacterial
Infections in Mice Lacking the Polypeptide (p)105 Precursor 
 
(NF-
 
k
 
B1) but Expressing p50
 
By Hideaki Ishikawa,
 
*
 
 Estefania Claudio,
 
*
 
 Donna Dambach,
 
‡
 
Carmen Raventós-Suárez,
 
*
 
 Carol Ryan,
 
*
 
 and Rodrigo Bravo
 
*
 
From 
 
*
 
the Department of Oncology, and 
 
‡
 
the Department of Experimental Pathology, Bristol-Myers 
Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000
 
Summary
 
The polypeptide (p)50 molecule, a subunit of nuclear factor (NF)-
 
k
 
B, is produced after pro-
teolytic processing of the p105 precursor (NF-
 
k
 
B1). Although the p105 precursor has been
postulated to play a role in the regulation of the Rel/NF-
 
k
 
B activity, its physiological rele-
vance remains unclear. To investigate that, we generated mutant mice lacking the COOH ter-
minal half of the p105 precursor, but expressing the p50 product (p105
 
2
 
/
 
2
 
). These mutant
mice displayed an inflammatory phenotype composed of lymphocytic infiltration in lungs and
liver, and an increased susceptibility to opportunistic infections. Enlargement of multiple lymph
nodes, splenomegaly due to erythrocytic extramedullary hematopoiesis, and lymphoid hyperplasia
were also observed in p105
 
2
 
/
 
2
 
 mice. Cytokine production in p105
 
2
 
/
 
2
 
 macrophages was severely
impaired, whereas proliferative responses of p105
 
2
 
/
 
2
 
 B cells were increased. T cell functions
were only moderately impaired in mutant mice. Loss of p105 also led to enhanced constitu-
tive p50 homodimer and inducible NF-
 
k
 
B activities in unstimulated and stimulated cells, re-
spectively. As several genes regulated by Rel/NF-
 
k
 
B were upregulated in p105
 
2
 
/
 
2
 
 thymus but
downregulated in p105
 
2
 
/
 
2
 
 macrophages, the enhanced p50 homodimers appear to function as
transcriptional activators or repressors, depending on the cell type. Thus, the p105 precursor is
indispensable in the control of p50 activity, and lack of the precursor has distinct effects on dif-
ferent cells.
 
N
 
uclear factor (NF)-
 
k
 
B plays an important role in reg-
ulating a wide variety of genes that encode proteins
involved in immune, acute phase, and inflammatory re-
sponses (1–4). Several NF-
 
k
 
B subunit molecules have been
identified that share extensive similarity to the 
 
rel
 
 protoon-
cogene product and the 
 
Drosophila
 
 maternal gene product
dorsal. In mammals, members of the Rel/NF-
 
k
 
B family
include NF-
 
k
 
B1 (p50 and its precursor p105), NF-
 
k
 
B2
(p52 and its precursor p100), RelA, RelB, and c-Rel. They
share a conserved NH
 
2
 
 terminus termed the Rel homology
domain (RHD)
 
1
 
 responsible for DNA binding, dimeriza-
tion, and association with I
 
k
 
B inhibitors. The unconserved
COOH terminus of RelA, RelB, and c-Rel mediates tran-
scriptional activation, whereas p50 and p52 do not contain
transcriptional activation domains. Mature p50 and p52
products are generated by removal of the COOH terminus
of the p105 and p100 precursors, respectively (3–9). The
genes of the Rel/NF-
 
k
 
B family are differentially expressed
in lymphoid tissues (10–12) and studies of mice lacking ei-
ther p50, RelA, RelB, or c-Rel demonstrate that individ-
ual members of this family have distinct functions in vivo
(13–17).
In most cells, the Rel/NF-
 
k
 
B complexes are associated
with inhibitory molecules, I
 
k
 
Bs, in the cytoplasm. The
Rel/NF-
 
k
 
B complexes can be rapidly induced by a variety
of stimuli leading to modifications of I
 
k
 
B proteins that al-
low dissociation of NF-
 
k
 
B-I
 
k
 
B complexes and subsequent
translocation of Rel/NF-
 
k
 
B complexes into the nucleus
(5–9, 18, 19). In mammals, members of the I
 
k
 
B family in-
clude I
 
k
 
B
 
a
 
, I
 
k
 
B
 
b
 
, I
 
k
 
B
 
g
 
, Bcl-3, p105, p100, and the re-
cently cloned I
 
k
 
B
 
e
 
 (20), which share the conserved
ankyrin-like repeats responsible for the interaction with the
Rel/NF-
 
k
 
B complexes. The 
 
trans
 
-acting I
 
k
 
B
 
a
 
 and I
 
k
 
B
 
b
 
may play a major role in controlling Rel/NF-
 
k
 
B activity,
whereas the p105 and p100 precursors can be regulators by
dimerizing with individual members of the Rel/NF-
 
k
 
B
family including their products p50 and p52 (4–7, 9, 19). In
the case of I
 
k
 
B
 
a
 
, phosphorylation of the NH
 
2
 
-terminal
serine residues induces complete degradation of the pro-
tein, whereas phosphorylation of NH
 
2
 
-terminal tyrosine
 
1
 
Abbreviations used in this paper:
 
 EMSA, electrophoretic mobility shift assay;
ES, embryonic stem; ICAM, intercellular adhesion molecule; mRNA, mes-
senger RNA; NF, nuclear factor; p, polypeptide; p(A), polyadenylation rec-
ognition sequence; PNA, peanut agglutinin; pPNT, plasmid PGK promoter
neomycin thymidine kinase; RT-PCR, reverse transcriptase PCR; VCAM,
vascular adhesion molecule.
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residues allows to release the Rel/NF-
 
k
 
B complexes with-
out protein degradation (21). Proteolytic cleavage and pre-
sumably subsequent degradation of the COOH-terminal
ankyrin region of the precursors (p105 and p100) also result
in Rel/NF-
 
k
 
B activation (9, 19). Degradation of both
I
 
k
 
B
 
a
 
 and the COOH terminus of p105 is mediated by a
ubiquitin–proteasome pathway, which requires previous
phosphorylation (22, 23). Recently, two I
 
k
 
B kinases have
been described; one of them is constitutive and requires
ubiquitination for being active (24) and the other, indepen-
dent of ubiquitination, is rapidly stimulated by cytokines as
TNF-
 
a
 
 and IL-1 (25).
The murine 
 
nfkb1
 
 gene produces two transcripts: one
4.0-kb messenger RNA (mRNA) encoding the full-length
polypeptide (p)105 precursor that is expressed ubiquitously,
and another 2.6-kb mRNA encoding the I
 
k
 
B
 
g
 
 protein iden-
tical to the COOH terminus of p105 that is found predom-
inantly in lymphoid cells (26, 27). These two transcripts are
likely to be generated by differential promoter usage.
To investigate the physiological role of p105, we gener-
ated mice lacking the precursor but still containing the p50
product by gene targeting. Mice homozygous for a dele-
tion of the COOH terminus of the p105 precursor devel-
oped an inflammatory phenotype in the lungs and liver,
and also had splenomegaly due to extramedullary hemato-
poiesis and lymphoid hyperplasia, enlarged lymph nodes,
and were susceptible to opportunistic infections. Cytokine
secretion in mutant macrophages was severely impaired,
whereas that in activated T cells appeared to be only
slightly decreased. Proliferative responses of p105
 
2
 
/
 
2
 
 T
cells were only moderately impaired, whereas those of
p105
 
2
 
/
 
2
 
 B cells were increased. The p50 homodimer
DNA-binding activity was increased in the absence of
p105, showing the regulatory role of the precursor for the
p50 homodimer activity. Moreover, the deregulated p50
homodimer activity is likely to function as a transcriptional
activator or repressor because the expression of several NF-
 
k
 
B–regulated genes was augmented in thymus but reduced
in macrophages from mutant mice.
 
Materials and Methods
 
Targeting Vector and Generation of Mutant Mice.
 
To generate the
targeting vector plasmid PGK promoter neomycin thymidine ki-
nase (pPNT)/I
 
k
 
B
 
g
 
 II, a small intronic sequence within the SV40
polyadenylation recognition sequences [SV40 p(A)] was deleted
in pPNT/I
 
k
 
B
 
g
 
 (28).
CJ7 embryonic stem (ES) cells were electroporated with the
NotI-linearized pPNT/I
 
k
 
B
 
g
 
 II, and subsequent double resistant
clones were selected as previously described (29). Homologous
recombination was screened by Southern blot using a 5
 
9
 
 external
probe. 5
 
9
 
,3
 
9
 
 internal or 
 
neo
 
-specific probes were used to demon-
strate that the targeted ES cell clones (5) did not contain any ran-
dom integration of the vector. Targeted clones were identified by
a novel 9-kb recombinant band in addition to the wild-type band
(
 
.
 
25 kb) in EcoRV-digested DNA when 5
 
9
 
 external or internal
probes were used. A 6.5-kb recombinant band in addition to the
11.2-kb wild-type band in EcoRI-digested DNA was also ob-
served in targeted ES clones when 5
 
9
 
 internal or 
 
neo
 
-specific
probes were used. The generation of chimeric mice, hetero-, and
homozygous mutant animals was performed as previously de-
scribed (29).
 
Histology, Immunohistochemistry, and Flow Cytometry.
 
Complete
postmortem examinations were performed on 3 wk-, 6 wk-, 12
wk-, and 5-mo-old mice. Organs were immersion-fixed in 10%
neutral buffered formalin, processed by standard methods, and paraf-
fin embedded. Tissue sections were stained with hematoxylin and
eosin for light microscopy. Immunohistochemical phenotyping
of hepatic and pulmonary inflammatory infiltrates was performed
using established avidin-biotin methods on serial, paraffin-embedded,
and frozen tissue sections with the following antibodies: B220 (B
cells; PharMingen, San Diego, CA), 7/4 (granulocytes; Serotec
Ltd., Oxford, UK), F4/80 (Serotec), Mac-2 (macrophages; Cedar
Lane, Hornby, Canada), and CD4 and CD8 (T cells; PharMingen).
Flow cytometry analysis was performed as previously described (17).
 
Western Blot Analysis and Electrophoretic Mobility Shift Assay.
 
Whole tissue extracts isolated from several organs of 3-wk-old
mice were prepared as described (30). Splenocytes or thymocytes
from 3-wk-old animals were isolated as described (31). Peripheral
B cells were purified from 3-wk-old mouse splenocyte suspension
by mouse B cell enrichment immunocolumns (Biotex Laboratories
Inc., Edmonton, Canada). Peripheral T cells were purified from
spleen or lymph nodes by murine T cell enrichment columns
(R&D Systems, Inc., Minneapolis, MN). Macrophages were col-
lected from 4-wk-old mice by peritoneal lavage and purified as
adherent cells to plastic dishes. B cells, T cells, and macrophages
were treated with 10 
 
m
 
g/ml of LPS (Sigma Chemical Co., St.
Louis, MO), 10 ng/ml of TNF-
 
a
 
 (Sigma Chemical Co.), and 10
 
m
 
g/ml of LPS, respectively. Nuclear extracts isolated from thy-
mocytes, B cells, T cells, or macrophages were prepared as de-
scribed (32). Western blot analysis using whole tissue extracts and
electrophoretic mobility shift assay (EMSA) using nuclear extracts
were performed as previously described (33). In brief, for EMSA
2–10 
 
m
 
g of nuclear extract were incubated at room temperature
for 30 min with a labeled probe in 20 
 
m
 
l of a solution containing
1 
 
m
 
g of poly dI:dC in 20 mM Hepes, pH 7.9, 10 mM MgCl
 
2
 
, 1
mM EDTA, 10% glycerol, 100 mM KCl, and protease inhibitor.
The DNA probes and Rel/NF-
 
k
 
B antibodies used in these studies
were described previously (28, 34).
 
Reverse Transcriptase-PCR Analysis.
 
Total RNA from 3-wk-
old mouse thymuses or macrophages was prepared using TRIzol
(GIBCO BRL, Gaithersburg, MD). Reverse transcriptase PCR
(RT-PCR) was performed as previously described (35). The
primer sequences consisted of: GM-CSF, 5
 
9-CCC ATC ACT
GTC ACC CGG CCT TGG-3 and 59-GTC CGT TTC CGG
AGT TGG GGG GC-39; IL-2, 59-GTC AAC AGC GCA CCC
ACT TCA AGC-39 and 59-GCT TGT TGA GAT GAT GCT
TTG ACA-39; TNF-b, 59-TCC TGA AAC CTG CTG CTC
ACC TTG TTG G-39 and 59-CTG GGG CTG AAG TGT
AGA TGG GAG ATG C-39; alpha inhibitor of kB (ikba), 59-TGG
CTG ACT GAC TCA CTG ACT GAC TGA CTC GTG CCT
TGC-39 and 59-TGG CCG TTG TAG TTG GTG GC-39; in-
tercellular adhesion molecule (ICAM)-1, 59-CCG CTT CCG
CTT CCG CTA CCA TCA CCG TGT ATT C-39 and 59-GCC
TTC CAG GGA GCA AAA CAA CTT CTG C-39; vascular
adhesion molecule (VCAM)-1, 59-AAC AGA CAG GAG TTT
TC-39 and 59-GTC AAC AAT AAA TGG TT-39. The se-
quences of the primers for b-actin and G-CSF were previously
described (29, 35). The primers for M-CSF and TNF-a were ob-
tained commercially (Stratagene Corp., La Jolla, CA).
Proliferation Assays. Purified B cells were treated with either
anti-IgM antibody (Jackson ImmunoResearch, Bar Harbor, ME) 
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or LPS, whereas purified T cells were treated with either coated
anti-CD3 antibody (PharMingen), coated anti-CD3 plus anti-
CD28 antibodies (PharMingen), or 7 ng/ml of PMA (Sigma
Chemical Co.) plus 1 
 
m
 
g/ml of PHA (Sigma Chemical Co.).
Proliferative responses were determined by [
 
3
 
H]thymidine incor-
poration as described previously (29).
 
Cytokine Production in T Cells and Macrophages.
 
Purified T cells
(5 
 
3
 
 10
 
5
 
/ml) were incubated with or without coated anti-CD3
antibody or coated anti-CD3 plus anti-CD28 antibodies for 24 h.
Purified peritoneal macrophages (5 
 
3
 
 10
 
5
 
/ml) were incubated in
the presence or absence of 1 
 
m
 
g/ml of LPS and 100 U/ml of IFN-
 
g
 
(Genzyme Corp., Cambridge, MA) for 72 h. Cytokine levels for
IL-1
 
b
 
, IL-4, IL-6, IL-10, GM-CSF, and TNF-
 
a
 
 in supernatants
were measured by ELISA (R&D Systems, Inc.); levels of IFN-
 
g
 
and IL-2 were also determined by ELISA (BIOSOURCE, Ca-
marillo, CA).
 
Analysis of Germinal Center Formation.
 
Three 6-wk-old mice
of each genotype were immunized intraperitoneally with 100 
 
m
 
l
of phosphate-buffered saline containing 10% SRBCs. 10 d later,
spleens were harvested, embedded in O.C.T. compound (Miles
Laboratories Inc., Rexdale, Canada), and frozen in liquid nitro-
gen. Frozen tissue sections were incubated with biotinylated
PNA (Vector Labs, Burlingame, CA) for centrocyte detection
and with rat anti–mouse IgD as previously described (36).
 
Immunoglobulin Isotype Assays.
 
Sera were prepared from 5-wk-old
sex-matched animals, and levels of Ig isotype were determined
using a sandwich ELISA using a pan-specific capture antibody
(Southern Biotechnology Assoc., Birmingham, AL) and isotype-
specific antibodies conjugated to horseradish peroxidase (Southern
Biotechnology Assoc.). For IgE levels, rat anti–mouse IgE capture
antibody (PharMingen), biotinylated rat anti–mouse IgE (Phar-
Mingen), and avidin peroxidase (Sigma Chemical Co.) were used.
 
T Cell–dependent and –independent Humoral Immune Responses.
 
5-wk-old sex-matched animals were immunized by intraperito-
neal injection of either 100 
 
m
 
g of KLH (Calbiochem Corp., La
Jolla, CA) coupled to (4-hydroxy-3-nitro-phenyl) acetyl (NP; Bio-
search Technologies, San Diego, CA) precipitated in alum (T cell–
dependent response) or 10 
 
m
 
g of LPS (
 
Escherichia coli
 
 0111: B4;
Difco, Detroit, MI) coupled to NP (T cell–independent response).
Conjugates at ratios of 17:1 (NP-KLH) and 10:1 (NP-LPS) and
alum precipitates were prepared as described (37, 38). Sera were
collected before immunization and at 7-d intervals after immuni-
zation for a period of 3 wk. Levels of NP-specific Ig isotypes
were determined by ELISA using NP-BSA (17:1) as a capture
agent and goat anti–mouse isotype-specific sera directly conju-
gated to horseradish peroxidase (Southern Biotechnology Assoc).
 
Results
 
Generation of Mice Lacking the COOH Terminus of NF-
 
k
 
B1.
 
The vector used to generate the p105
 
2
 
/
 
2
 
 was de-
scribed previously (27), except for the deletion of a small
intron within the SV40 p(A) to avoid an alternative RNA
splicing, which produced a p50 isoform lacking the nuclear
localization signal (NLS; Fig. 1 
 
A
 
).
The new targeting vector (PNT/I
 
k
 
B
 
g
 
II) was electropo-
rated into CJ7 ES cells and double resistant clones were
screened by Southern blot analysis as described previously
(28). Chimeric mice generated by standard procedures
transmitted the mutation of the 
 
nfkb1
 
 locus to their off-
spring, and subsequent intercrosses between heterozygotes
generated homozygous mutant (p105
 
2
 
/
 
2
 
) mice. The three
different genotypes are shown by Southern blot analysis us-
ing genomic DNA isolated from mouse tails (Fig. 1 
 
B
 
).
Western blot analysis using whole tissue extracts isolated
from the thymus demonstrated a lack of p105 but the pres-
ence of p50 in homozygous mutant mice (Fig. 1 
 
C
 
). A
faster migrating molecule reactive to a p50 antibody was
detected in p105
 
2
 
/
 
1
 
 or p105
 
2
 
/
 
2
 
 extracts, despite a deletion
of SV40 p(A) intronic sequences; however, the expected
p50 molecule of 415 amino acids was very abundant in the
mutants. The signal corresponding to the I
 
k
 
B
 
g
 
 protein
could not be detected in control extracts when an I
 
k
 
B
 
g
 
-
specific antibody was used (data not shown). This is in
agreement with previous observations indicating the ex-
Figure 1. Generation of p1052/2 mice. (A) Targeting strategy of the
ankyrin-encoding region of the nfkb1 gene. The relevant structure of the
murine nfkb1 gene is shown at the top. Targeting vector pPNT/IkBg II
and the targeted allele are shown at the middle and bottom, respectively.
Closed boxes, exons of nfkb1 gene; open boxes, the SV40 p(A), phospho-
glycerate kinase (PGK)-neo, and PGK-tk cassettes. The position of EcoRI
and EcoRV sites are indicated by I and V, respectively. The diagnostic re-
striction fragments used for Southern blot analysis are indicated at the top
(wild-type allele) and bottom (targeted allele). The DNA fragments used
as 59 external (EE), 59 internal (XX), 39 internal (E), and neo-specific
(PP620) probes are indicated at the bottom. (B) Genotype analysis of pups
generated from p1051/2 intercrosses. Tail DNAs were digested with
EcoRI, followed by Southern blot analysis using the 59 internal probe
XX. The wild-type allele is indicated by a 11.2-kb band, whereas the re-
combinant allele is represented by a 6.5-kb band. (C) Lack of p105 in ho-
mozygous mutants. Whole tissue extracts from thymus were subjected to
Western blot analysis using a p50 antibody. Specific signals for the p50
isoform, p50, and p105 proteins are indicated by arrows.
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tremely low abundance of the IkBg protein and expression
of the IkBg transcript in a restricted population of cells
(26, 27).
Increased Mortality and Histological Abnormalities of p1052/2
Mice. Heterozygotes mating produced the normal num-
ber of homozygous mutant mice (21.5%, n 5 297) accord-
ing to mendelian ratios. During the first 3 wk of age, ho-
mozygous mutant mice were similar in size and weight to
littermates, although 20% of p1052/2 pups died. After
weaning, some p1052/2 pups appeared sick (rough haircoat
and lethargic) and showed growth retardation (data not
shown). Later, some of these pups maintained in conven-
tional housing developed eye and/or nasal infections pro-
duced by Staphylococcus xylosis and Pasteurella haemolytica
(opportunistic bacteria), whereas mice maintained in mi-
croisolators did not show infections. p1052/2 mice started
to die at an increased rate after 2 mo of age, resulting in a
50% survival (n 5 15) at 100 d old, whereas control litter-
mates (p1051/1 and p1052/1, n 5 22) showed almost
100% survival by 7 mo of age (Fig. 2 A).
Although 3-wk-old p1052/2 mice had unremarkable
histology, 6-wk-old animals developed an abnormal phe-
notype, which worsened with age. Histological alterations
consistently occurred in the spleen, lymph nodes, lung,
liver, and bone marrow. p1052/2 mice had a variable de-
gree of splenic and lymph node enlargement at postmortem
examination. In young mice, splenomegaly was not only
due to erythrocytic extramedullary hematopoiesis, but also
Figure 2. Gross abnormalities of p1052/2 mice. (A) Mortality of control and heterozygotes (circles, n 5 22) and p1052/2 (triangles, n 5 15) mice. Sur-
vival is shown as a percentage of the total initial number of control or p1052/2 mice. (B) Histopathology of p1052/2 mice. Spleen (a and b), lymph node
(LN; c and d), lung (e and f), and liver (g and h) from 6-wk-old, and bone marrow (BM; i and j) from 12-wk-old control (1/1; a, c, e, g, and i) and
p1052/2 (2/2; b, d, f, h, and j) animals stained with hematoxylin and eosin. Marked enlargement of the spleen and lymph node in mutant mice (inset, a
and b, increased erythrocytic extramedullary hematopoiesis; the white pulp was also expanded). The paracortical area of lymph nodes are expanded in
mutant mice, but overall lymphocyte numbers are decreased (inset, c and d). The liver and lung contain perivascular lymphoid infiltration in mutant mice.
Relative hyperplasia in the bone marrow with an associated decrease in erythrocytic precursor cells in mutant mice. (C) Splenic sections from 6-wk-old
control (1/1; a and c) and p1052/2 (2/2; b and d) mice immunized with SRBCs. Sections were incubated with rat anti–mouse IgD (a and b) and bi-
otinylated PNA (c and d). Mantle zones in mutant mice are less compact (compare a and b). The PNA positive cell area corresponding to centrocytes is
markedly expanded in the mutant mice as compared to the control animals (compare c and d). Original magnifications: 2 B, a and b, 62.5; c and d, 125; e
and f, 250; g and h, 500; i and j, 1,000; inset, a and b, 500; and inset, c and d, 2,500; 2 C, 125.989 Ishikawa et al.
to an expansion of the follicular areas with a loss of mantle
and marginal zone definition (Fig. 2 B, compare a with b).
All lymph nodes examined had variable degrees of paracor-
tical zone expansion without an increase in lymphoid cells
(Fig. 2 B, compare c with d). In addition, lungs and liver of
p1052/2 mice had mild–moderate perivascular, periairway,
and periportal mixed infiltration of inflammatory cells, re-
spectively (Fig. 2 B, e–h), which were mainly composed of
lymphocytic cells (CD41 and B2201 cells; data not shown).
Myeloid hyperplasia was present in the bone marrow asso-
ciated with a decrease in erythrocytic cells (Fig. 2 B, com-
pare i and j).
To analyze in more detail the splenic B cell compart-
ment, immunohistochemical evaluation of the spleens from
mice immunized with SRBCs was performed. There were
prominent peanut agglutinin (PNA)-staining cells in the
central area (centrocytes), and these areas were surrounded
by a compact zone of IgD1 cells (Fig. 2 C, compare a with
b). The B cell area was markedly expanded in immunized
mutant mice, but discrete germinal centers were not present.
The PNA-staining cell area was enlarged, and the IgD1 cell
area was less compact compared to wild-type mice (Fig. 2
C, c–d).
Flow cytometry revealed alterations in the hematopoi-
etic cell population in 6-wk-old p1052/2 mice (Fig. 3). The
thymus from 6-wk-old mice contained a normal distribu-
tion of T cells as compared to wild-type animals (Fig. 3 A,
a and b). However, there was a significant decrease of
CD41 and CD81 T cells in both spleen and lymph node
(Fig. 3 A, compare c with d; lymph node, data not shown).
The reduction of the peripheral T cell population was
more evident when the Thy 1.2 antibody was used (Fig. 3
B). The number of the Thy 1.21 cells in the mutant mice
were reduced by 50% as compared to the wild-type mice.
Erythroblasts accumulated in mutant spleen (Fig. 3 A, e and
f) consistent with the histological results showing increased
extramedullary hematopoiesis in the spleen (Fig. 2 B). The
bone marrow had a decrease in the erythroblasts and only a
slight increase in the granulocyte population (Fig. 3 A,
compare g with h), also consistent with the histological
findings.
Enhanced  kB-binding Activities in p1052/2 Mice. The p105
precursor, as well as p100 (NF-kB2) have been shown to
act as an inhibitor of NF-kB activities by trapping members
of Rel/NF-kB family in the cytoplasm (39–42). Therefore,
we investigated the effect of the lack of p105 on nuclear
kB-binding activities in several tissues of 3-wk-old animals
by EMSA (Fig. 4 A, top). The p1052/2 mice had an in-
crease in p50 homodimer kB-binding activity in some tis-
sues, such as spleen, thymus, and liver, compared to wild-
type tissues. Oct-1–binding activities were used as a loading
control (Fig. 4 A, bottom). By Western blot analysis, consti-
tutive expression of p50 was more abundant in lymphoid
tissues (spleen, thymus, lymph node, and bone marrow)
and in higher concentrations in extract from mutant mice
(data not shown). To analyze the composition of the differ-
ent migrating bands present in spleen extracts, EMSA was
performed in the presence of antibodies directed against the
different Rel/NF-kB proteins. Anti-p50 antiserum was
able to remove the faster migrating complexes (band I),
suggesting that this band is composed of p50 homodimers.
The slower complexes (band II) show two different bands;
the lower one was eliminated with anti-p50 and anti-RelA
antiserum suggesting that it corresponds to p50/RelA het-
erodimers. The fact that the upper band reacted with anti-
p50 antiserum but not anti-RelA, -RelB, and -p52 antisera,
lead us to postulate that it represents p50/cRel complexes
(Fig. 4 B).
We also analyzed the nuclear kB-binding activities in
purified B cells, T cells, and macrophages. As shown in Fig.
4 C, although the absence of p105 augmented the constitu-
tive kB-binding in all three cell types, the p50 homodimers
were markedly increased in p1052/2 T cells and macro-
phages relative to B cells. Compared to wild type, the induced
NF-kB activity (band II) was also augmented in p1052/2
cells after stimulation, probably because of the degradation
of IkBa. This is expected because the increase of p50 may
Figure 3. Flow cytometry analysis of hematopoietic cells in p1052/2
mice. (A) Thymocytes stained for CD4 and CD8 (a and b), splenocytes
stained for CD4 and CD8 (c and d) or Mac-1 and Ter 119 (e and f), and
bone marrow cells stained for Gr-1 and Ter 119 (g and h) from 6-wk-old
control (1/1; a, c, e, and g), and p1052/2 (2/2; b, d, f, and h) mice. Per-
centages of positive cells are indicated. (B) Histogram of the relative num-
ber of splenocytes stained with B220 (a and b) or Thy 1.2 (c and d) from
6-wk-old control (1/1; a and c), and p105 2/2 (2/2; b and d).990 p105-deficient Mice
lead not only to an augment in p50 homodimers, but also
of p50 heterodimers, which can associate with IkBa.
Expression of Genes Regulated by Rel/NF-kB. The mRNA
levels of genes assumed to be regulated by Rel/NF-kB
were examined to determine whether their expression was
effected by the increased p50 homodimer activity present
in p1052/2 mice. Semiquantitative RT-PCR analysis using
total RNA isolated from the thymuses of 3-wk-old animals
showed that G-CSF, GM-CSF, M-CSF, IL-2, and TNF-b
expression was upregulated in p1052/2 mice (Fig. 5 A),
whereas the mRNA levels of ICAM-1, ikba, IFN-b, IL-6,
class I MHC, macrophage inflammatory protein (MIP)-2,
c-myc, nfkb2, TNF-a, and VCAM-1 (Fig. 5 A and data
not shown) were similar between control and p1052/2
mice. Interestingly, none of the genes analyzed was down-
regulated in thymus of p1052/2 mice, but some were up-
regulated, suggesting that p50 homodimers could activate
gene transcription in certain cell types. However, we can-
not eliminate the possibility that the increased gene expres-
sion observed in some of these cytokines is due to the small
augment in heterodimeric complexes.
In contrast, mRNA levels of some cytokines in resident
peritoneal macrophages revealed significant differences be-
tween wild-type and p1052/2 cells as shown in Fig. 5 B.
The levels of GM-CSF, TNF-a, IL-6, and ICAM-1 in res-
ident macrophages were decreased compared with control.
Interestingly, there also was a difference in the mRNA lev-
els of cytokines in elicited macrophages between mutant
and wild-type mice. Expression levels of genes such as IL-6,
ICAM-1, and VCAM were downregulated, whereas ex-
pression levels of TNF-a and G-CSF were similar to wild-
type cells (data not shown). These findings suggest that p50
homodimers can activate or inhibit gene transcription of
some cytokines in a cell type–dependent manner.
Figure 4. Accumulation of the p50 homodimer activity in p1052/2
mice. Increased kB-binding activity in several tissues of p1052/2 mice.
(A) Nuclear extracts (2 mg) from spleen, thymus, lung, liver, stomach, and
pancreas were used for EMSA. A kB palindromic sequence was used to
detect the kB-binding activities. The octamer-specific motif was used as a
control. (B) Nuclear extracts from spleen were incubated with a palindro-
mic kB-binding site and treated with specific antisera against the different
members of the Rel/NF-kB family before EMSA. P.I., preimmune se-
rum. (C) Induction of NF-kB activity after stimulation of different cells.
Nuclear extracts from untreated control and p1052/2 B cells, T cells, and
macrophages or treated with LPS (B cells and macrophages) or TNF-a (T
cells) for the indicated period were analyzed by EMSA using a kB probe.
NF-kB heterodimers and p50 homodimers are indicated as band II and I,
respectively.
Figure 5. Dual role of p50 homodimers in gene expression in p1052/2
mice. (A) Total RNA (0.5 mg) isolated from thymus of 3-wk-old animals
or (B) total RNA (2 mg) isolated from resident macrophages of 4-wk-old
animals was used for RT-PCR analysis using specific primers as indicated.991 Ishikawa et al.
Proliferative Responses of p1052/2 Lymphocytes. Prolifer-
ative responses of B or T cells purified from 3-wk-old
mouse spleens were analyzed by [3H]thymidine incorpora-
tion. Both anti-IgM antibody and LPS promoted prolifera-
tion of mutant and wild-type B cells. However, at low
concentrations of the stimuli, there was an increased prolif-
erative responses of p1052/2 B cells (four to fivefold; Fig. 6
A). In contrast, p1052/2 T cells stimulated with anti-CD3
or anti-CD3 plus anti-CD28 did not proliferate as effi-
ciently as control T cells (two to threefold reduction), but
p1052/2 T cells stimulated with PMA plus PHA exhibited
similar proliferation rates to controls (Fig. 5 B). The defects
of proliferative responses observed in p1052/2 T cells were
not found in p1051/2 T cells (data not shown). These re-
sults indicate that loss of the p105 precursor has a different
effect on B and T cells.
Cytokine Production in p1052/2 T Cells and Macrophages.
Cytokine production in T cells isolated from spleen and in
macrophages by peritoneal lavage of 3-wk-old mice was
analyzed by ELISA. The levels of IFN-g, IL-10, and GM-
CSF released from T cells stimulated with anti-CD3 or anti-
CD3 plus anti-CD28 antibodies were comparable between
wild-type and p1052/2 T cells, whereas the levels of IL-2,
IL-4, and TNF-a produced in mutant T cells were de-
creased (three to sixfold) compared to control cells (Fig. 7 A).
Both unstimulated and stimulated p1052/2 resident peri-
toneal macrophages showed lower cytokine production
compared to wild-type cells (17–86-fold reduction in un-
stimulated; 2–8-fold reduction in stimulated mutant cells
relative to control). Some of the cytokine levels were un-
detectable in unstimulated mutant macrophages (Fig. 7 B).
Cytokine production in elicited peritoneal macrophages
from mutant mice was also impaired (data not shown).
Basal and Specific Antibody Production. To assess basal pro-
duction of antibodies in naive mice, we measured resting
serum immunoglobulin levels in p1052/2 mice and control
littermates. Levels of total serum Ig were increased fivefold
in p1052/2 mice (Fig. 8 A). These levels resulted from a
significant increase in most Ig isotypes, except for IgG3.
The levels of IgE and IgG1 were especially increased in
p1052/2 sera (50- and 18-fold relative to wild type, respec-
tively), whereas those of IgG3 were significantly reduced
(4-fold). These results indicate that heavy chain class switching
of p1052/2 B cells is not impaired, confirming the findings
from nfkb12/2 mice showing that p50 is required for nor-
mal Ig isotype levels and class switching (16, 43).
The tendency of increased basal immunoglobulin levels
prompted us to examine whether humoral immune re-
sponses were affected in p1052/2 animals. Mice were im-
munized with T cell–dependent antigen NP-KLH or T
cell–independent antigen NP-LPS, and production of spe-
cific antibodies was measured at 1, 2, and 3 wk after immu-
nization. The production of IgG1 in response to NP-KLH
was increased in p1052/2 mice two to threefold compared
to wild-type animals at 2 and 3 wk after injection (Fig. 8 B)
showing that the lack of the p105 precursor does not nega-
tively affect the T cell–dependent immune response. When
we analyzed the production of IgG3 in response to NP-
Figure 6. Proliferative responses of lym-
phocytes. (A) B cell proliferation. [3H]Thy-
midine incorporation of splenic B cells from
3-wk-old control (closed circles) or p1052/2
(open circles) mice treated for 48 h with the
indicated concentrations of either anti-IgM
or LPS. Values of [3H]thymidine incorpora-
tion are shown by mean 6 SD. (B) T cell
proliferation. [3H]Thymidine incorporation
of splenic T cells from 3-wk-old control
(closed bars) or p1052/2 ( open bars) mice
treated for 48 h with either PMA plus PHA,
anti-CD3, or anti-CD3 plus anti-CD28.992 p105-deficient Mice
LPS, the levels of specific immunoglobulin obtained were
similar to those of the wild-type mice at 1 or 2 wk after
immunization; however, at 3 wk, the levels of specific
IgG3 were reduced threefold (Fig. 8 C). These results sug-
gest that the lack of p105 and IkBg does not seriously affect
the production of basal and specific antibody production.
Discussion
In this study we showed that targeted disruption of the
COOH-terminal ankyrin domain of NF-kB1, which elim-
inates both p105 and IkBg but not p50, induced multiple
abnormalities, such as inflammation in lungs and liver, my-
eloid hyperplasia in bone marrow, enlarged lymph nodes,
and splenomegaly, presumably due to the accumulated p50
homodimer kB-binding activity. Moreover, p1052/2 mice
were apparently susceptible to bacterial infections, which
may result from the impaired cytokine production in mac-
rophages. In addition, p1052/2 mice had different abnor-
malities from mice lacking the COOH terminus of NF-
kB2 (p1002/2; reference 29), demonstrating the distinct
physiological roles between NF-kB1 and NF-kB2.
Mice that lacked the p105 precursor and IkBg but
mainly expressed a nuclear localization signal–deficient p50
isoform instead of an expected p50 of 415 amino acids (28),
did not have any of the abnormalities described here for the
p1052/2 mice, and showed almost 100% survival by 1 yr of
age (Ishikawa, H., unpublished observations). These find-
ings indicate that the absence of p105 by itself is not suffi-
cient to trigger the phenotype observed in p1052/2 mice
and that the presence of active p50 molecules is necessary.
This is further supported by the fact that p50-deficient
mice (16) that lack both the p105 precursor and the p50
molecules do not present the alterations observed in p1052/2
mice, strongly suggesting that the increased p50 homodimer
activity contributes to the abnormalities in p1052/2 mice.
Inflammatory Phenotype and Hematopoietic Abnormalities of
p1052/2 Mice. Inflammation consisting of perivascular
lymphocytic infiltrates was developed in lungs and liver of
p1052/2 mice at 6 wk of age. The perivascular region in
Figure 7. Cytokine production in T cells or macrophages. (A) Secretion of IL-2, IL-4, and TNF-a is decreased in p1052/2 T cells. Splenic T cells pu-
rified from 3-wk-old control (closed bars) or p1052/2 (open bars) untreated (1) or treated with anti-CD3 (2) or anti-CD3 plus anti-CD28 (3) for 24 h. The
cytokine levels in the supernatants were determined by ELISA. (B) Cytokines released from macrophages. Peritoneal macrophages purified from 3-wk-old
mice untreated (2) or treated with (1) LPS and IFN-g for 72 h. The cytokine levels are indicated by mean values 6 SD.993 Ishikawa et al.
the lung and the periportal area in the liver are the topo-
graphical sites for initial antigen exposure; therefore, the
inflammatory infiltrates observed in p1052/2 mice in this
study may represent an exaggerated response to innocuous
antigens and a defect in the natural immune response. A
similar mechanism has been proposed to explain the in-
flammatory response in IL-2, GM-CSF, and RelB knock-
out mice (17, 44, 45).
Enlargement of multiple lymph nodes and splenomegaly
was consistently observed in p1052/2 mice from 6 wk of
age onwards. In both of these secondary lymphoid organs,
B and T cell compartments had alterations; however, mu-
tant animals were still able to produce germinal centers. In
fact, the PNA-positive regions in p1052/2 mice were en-
larged due to marked hyperplasia of centrocytes. The in-
crease in the proliferation rate of some B cell populations in
p1052/2 mice may be due to the allowance of greater
numbers of p50 to associate with cofactors such as Bcl-3.
The results obtained in previous studies examining the as-
sociation of p50 and Bcl-3 also suggest that Bcl-3 is a co-
factor for p50 (12, 46, 47). On the other hand, the analyses
of Bcl-3 knockout mice suggest a functional interaction
between Bcl-3 and p50 in vivo (48, 49). Both p502/2 and
Bcl-32/2 mice develop susceptibility to infections and they
are not able to produce specific antibodies (16, 48, 49);
however, only Bcl32/2 mice show a deficient germinal
center formation.
The bone marrow changes observed in p1052/2 mice af-
ter 12 wk of age were interpreted histologically as a mye-
loid hyperplasia due to the predominance of myeloid pre-
cursors relative to megakaryocytes and erythroid precursors.
However, by flow cytometry analysis, the percentage of
myeloid cells does not show a significant increase compared
to control mice, whereas the erythroid cell number was de-
creased. Taken together, the histological and flow cytometry
findings are consistent with a primary erythroid hypoplasia.
The increased erythrocytic extramedullary hematopoiesis
in spleen may have been caused, in part, by the decrease of
erythroid cells in bone marrow, although the cause of this
decrease is unknown. Indeed, peripheral blood cell counts
were consistently normal in mutant mice at all ages exam-
ined, presumably due to the extramedullary hematopoiesis.
It is also interesting to note that some of the abnormali-
ties in p1052/2 mice resemble those observed in RelB-
deficient mice, such as inflammation in lungs and liver,
myeloid hyperplasia in bone marrow, and splenomegaly
(17). The augmented p50 homodimers would be able to
have a displacement effect on the RelB-containing NF-kB
transcription complexes that are shown to contribute to the
constitutive kB-binding activities (12).
Immune Functions in p1052/2 Mice. The susceptibility to
opportunistic infections in the mucocutaneous areas in mu-
tant mice at 6 wk of age and older suggests defects in nor-
mal killing and clearing of bacteria by neutrophils and mac-
Figure 8. Basal and specific Ig pro-
duction in vivo. (A) Ig isotype concen-
trations. The concentration of serum Ig
in unimmunized control (closed circles),
heterozygotes (closed triangles), and
p1052/2 ( open circles) mice was deter-
mined by isotype-specific ELISA. (B) T
cell–dependent antibody production.
Mice were immunized with NP-KLH
and the levels of NP-specific IgG1 were
determined 1, 2, and 3 wk after immu-
nization. (C) T cell–independent anti-
body production. Mice were immu-
nized with NP-LPS and the levels of
NP-specific IgG3 were determined 1, 2,
and 3 wk after immunization. Each
symbol represents the value obtained
from one animal. Horizontal bars, mean
values.994 p105-deficient Mice
rophages. As both cell types are known to be primarily
responsible for protection from most bacterial infections by
nonspecific phagocytosis, their altered functions contribute
to inefficient immune responses. The impaired recruitment
of macrophages and PMNs after peritonitis induction in
mutant mice (data not shown) suggests also a defect in the
function of these cells. Moreover, the ability of p1052/2 B
cells to produce antibodies, which is also important for kill-
ing bacteria, was normal. T cells had alterations in the pro-
duction of some cytokines such as IL-2, IL-4, and TNF-a.
As cytokines have a pluripotent effect on the immune net-
work, the impaired production in T cells may also contrib-
ute to the immune defects observed in p1052/2 mice.
Interestingly, the proliferative rate of B cells from mutant
mice in response to several stimuli was increased, but that
of T cells was decreased. The differences between different
kinds of cells may imply a dual role for p50 in vivo. This
was also found in Bcl-32/2 mice (48, 49).
The analysis of basal and specific Ig production showed
Ig heavy chain class switching was not impaired in the ab-
sence of p105. Interestingly, in contrast to p502/2 mice,
which have markedly reduced levels of some Ig, all of those
isotypes were markedly increased in p1052/2 mice, imply-
ing that the p50 homodimers play a role in enhancing Ig
heavy chain class switching. Alternatively, the increase of
total number of B cells in peripheral organs may result in a
relative accumulation of Ig levels in p1052/2. In addition,
T cell–dependent and –independent immune responses in
p1052/2 mice are not seriously impaired; on the contrary,
the specific Ig production in p502/2 mice is completely
impaired (16).
The Roles of the p105 Precursor. The p105 precursor,
like IkB, is postulated to regulate Rel/NF-kB activities by
dimerizing with subunits of Rel/NF-kB and retaining
them in the cytoplasm, and also its proteolytic processing
controls the availability of p50 molecules (2, 4, 7, 8). Elim-
ination of the precursor simultaneously results in accumula-
tion of p50 that may contribute to forming both ho-
modimers and heterodimers. In the absence of p105, the
p50 homodimers appeared fully active, whereas the p50-
containing heterodimers seemed to be inactivated by IkB
molecules. Indeed, the induced NF-kB activities were in-
creased relative to control after stimulation of the cells (see
Fig. 4 C). Moreover, subcellular localization of RelA was
not altered in p1052/2 thymocytes and splenocytes (data
not shown), indicating that in the case of RelA-containing
NF-kB complexes, such as p50-RelA, loss of p105/IkBg
could be completely compensated by the other IkB pro-
teins. This is in agreement with our previous observation
that overexpression of RelA in thymocytes does not signif-
icantly increase kB-binding activity due to a concomitant
increase in IkBa levels (50). It is also important to note that
mice lacking IkBa exhibit skin defects, granulocytosis, and
activation of NF-kB activity composed of p50–RelA het-
erodimers, resulting in neonatal lethality (51, 52). This sug-
gests that IkBa is mainly involved in the regulation of the
p50–RelA heterodimer activity, and that the constitutively
activated p50–RelA complex found in IkBa-deficient
mice, presumably causes the abnormalities. As p105 forms
dimers with its product p50 and retains it in the cytoplasm,
the precursor is important for controlling, in particular, the
p50 homodimer activity that is unlikely to be regulated by
IkBa or IkBb. The p105 precursor shares structural char-
acteristics with another member of Rel/NF-kB family, the
p100 precursor. Both proteins contain in the COOH ter-
minus an ankyrin-like domain mediating kB inhibitor
function and by proteolytic cleavage generate the functional
p50 and p52 subunits, respectively. However, the distinct
expression pattern of nfkb1 and nfkb2 transcripts in the em-
bryo and adult mouse may indicate different roles for these
molecules (12). Moreover, the findings obtained from the
mutant mice lacking either p100 (28) or p105, described
here, reinforce the functional differences between these
proteins. Mutant mice lacking the p100 precursor devel-
oped a marked gastric hyperplasia and an increase in the
kB-binding activities composed of mainly heterodimers
containing p52, whereas mice lacking p105 had an inflam-
matory phenotype and an increase in kB-binding activities
consisting mainly of the p50 homodimers.
The Biological Activity of the p50 Homodimers. The answer
to the question of whether the p50 homodimers can be
transcriptional activators or repressors still remains contro-
versial. Most previous findings demonstrate that they have
an antagonistic effect on the classical NF-kB transcription
factor activity through the kB motif in cells (2, 8), whereas
others demonstrated that they can activate transcription in
cell-free systems (53, 54). The p50 homodimer, in associa-
tion with Bcl-3, which is structurally related to IkBs, has
been shown to have the ability to activate transcription in
cells (46, 47). More recently, nfkb12/2 mice were shown to
have reduced IL-6 but augmented IFN-b gene expression
(16). However, since nfkb12/2 mice contain neither the
p50 homodimers nor the p50-containing heterodimers,
most typically p50–RelA, those animals do not provide a
clear answer to this question.
In this study, we show that the p50 homodimers may
function as transcriptional activators or repressors depend-
ing on the cell types. In vitro analysis, such as proliferative
responses and cytokine production, revealed that the ab-
sence of p105 had a dual effect on different cell types. The
induced NF-kB, most likely p50–RelA heterodimers, may
have a much stronger transcriptional activity than the p50
homodimers based on numerous previous in vitro studies.
In p1052/2 B cells, the induced NF-kB may overcome the
small amount of p50 homodimer activity, whereas in
p1052/2 T cells and macrophages, the high levels of p50
homodimers may still efficiently compete with the induced
NF-kB activity. According to this hypothesis, in stimulated
cells the p50 homodimers may act like antagonists because
of the weak transcriptional activity relative to the het-
erodimeric NF-kB. Alternatively, there may be cell-spe-
cific cofactors that interact with the p50 homodimers and
can activate gene expression. This may also explain a dual
effect of the p50 homodimer activity on different cell lin-995 Ishikawa et al.
eages. As described above, it is reasonable to speculate that
Bcl-3 is a possible candidate as a cofactor, although expres-
sion of the Bcl-3 protein in different cell types has not been
extensively examined. Mice lacking both p105 and Bcl-3
may be helpful to gain an insight into this possibility.
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